Prognosis of Incidental Pulmonary Embolism Vs. Symptomatic Pulmonary Embolism in Cancer Patients: a Single-center Retrospective Cohort Study in China

Overview

Journal Thromb J

Publisher Biomed Central

Date 2023 Jun 6

PMID 37280671

Authors

Yanfei Wang

Zhongfen Liu

Qiuyu Li

Lina Xia

Yunyi Wang

Danfeng Jiang

Xiaoyan Chen

Yanqun Zheng

Wei Liu

Dan Wang

Dong Xue

Affiliations

Soon will be listed here.

Abstract

Background: The incidence of incidental pulmonary embolism (IPE) has greatly increased, but its clinical characteristics and outcomes are still controversial. This study aimed to compare the clinical characteristics and outcomes between cancer patients with IPE and patients with symptomatic pulmonary embolism (SPE).

Patients/methods: Clinical data of 180 consecutive patients with cancer complicated with pulmonary embolism admitted to Beijing Cancer Hospital from July 2011 to December 2019 were retrospectively collected and analysed. General characteristics, diagnosis time of pulmonary embolism (PE), location of PE, concurrent deep venous thrombosis, anticoagulant treatment, impact of PE on anti-tumor treatment, recurrent venous thromboembolism, rate of bleeding after anticoagulation therapy, survival and risk factors of IPE were compared with SPE.

Results: Of 180 patients, 88 (49%) had IPEs and 92 (51%) had SPEs. Patients with IPE and SPE did not differ in age, sex, tumor type, or tumor stage. Median diagnosis times of IPE and SPE after cancer were 108 (45, 432) days and 90 (7, 383) days, respectively. Compared to SPE, IPE tended to be central (44% versus 26%; P < 0.001), isolated (31.8% versus 0.0%; P < 0.001), and unilateral (67.1% versus 12.8%; P < 0.00). The rate of bleeding after anticoagulation therapy did not differ between IPE and SPE. Patients with IPE had a better prognosis than patients with SPE in terms of 30-, and 90-day mortality, as well as overall survival after diagnosis of PE (median: 314.5 vs. 192.0 days, log-rank P = 0.004) and cancer (median: 630.0 vs. 450.5 days, log-rank P = 0.018). SPE (compared to IPE) was an independent risk factor for poor survival after diagnosis of PE in multivariate analysis (hazard ratio [HR] = 1.564, 95% confidence interval [CI]: 1.008-2.425, p = 0.046).

Conclusions: IPE accounts for nearly one half of PE cases among Chinese cancer patients. With active anticoagulation treatment, IPE is expected to achieve better survival rates than SPE.

References

den Exter P, Hooijer J, Dekkers O, Huisman M . Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol. 2011; 29(17):2405-9. DOI: 10.1200/JCO.2010.34.0984. View

Mo M, Yamashita Y . Are We Overtreating Incidental Pulmonary Embolism?　- Reply. Circ J. 2021; 85(9):1691. DOI: 10.1253/circj.CJ-21-0578. View

Elting L, Escalante C, Cooksley C, Avritscher E, Kurtin D, Hamblin L . Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004; 164(15):1653-61. DOI: 10.1001/archinte.164.15.1653. View

Kearon C, Ageno W, Cannegieter S, Cosmi B, Geersing G, Kyrle P . Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016; 14(7):1480-3. DOI: 10.1111/jth.13336. View

Alotaibi G, Wu C, Senthilselvan A, Sean McMurtry M . Short- and long-term mortality after pulmonary embolism in patients with and without cancer. Vasc Med. 2018; 23(3):261-266. DOI: 10.1177/1358863X18754692. View

Dentali F, Ageno W, Becattini C, Galli L, Gianni M, Riva N . Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res. 2010; 125(6):518-22. DOI: 10.1016/j.thromres.2010.03.016. View

Barca-Hernando M, Ortega-Rivera R, Lopez-Ruz S, Elias-Hernandez T, Asensio-Cruz M, Marin-Romero S . Prognostic Significance of Incidental Deep Vein Thrombosis in Patients with Cancer Presenting with Incidental Pulmonary Embolism. Cancers (Basel). 2020; 12(8). PMC: 7463961. DOI: 10.3390/cancers12082267. View

Stevens S, Woller S, Kreuziger L, Bounameaux H, Doerschug K, Geersing G . Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021; 160(6):e545-e608. DOI: 10.1016/j.chest.2021.07.055. View

Klok F, Huisman M . Management of incidental pulmonary embolism. Eur Respir J. 2017; 49(6). DOI: 10.1183/13993003.00275-2017. View

10.

Ming Tsang N, Pai P, Chuang C, Chuang W, Tseng C, Chang K . Overweight and obesity predict better overall survival rates in cancer patients with distant metastases. Cancer Med. 2016; 5(4):665-75. PMC: 4831285. DOI: 10.1002/cam4.634. View

11.

Font C, Farrus B, Vidal L, Caralt T, Visa L, Mellado B . Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Ann Oncol. 2011; 22(9):2101-2106. DOI: 10.1093/annonc/mdq720. View

12.

Schulman S, Kearon C . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4):692-4. DOI: 10.1111/j.1538-7836.2005.01204.x. View

13.

Delluc A, Wang T . How to treat incidental pulmonary embolism in cancer patients? Recent advances. Kardiol Pol. 2021; 79(12):1305-1310. DOI: 10.33963/KP.a2021.0164. View

14.

Meyer H, Wienke A, Surov A . Incidental pulmonary embolism in oncologic patients-a systematic review and meta-analysis. Support Care Cancer. 2020; 29(3):1293-1302. PMC: 7843533. DOI: 10.1007/s00520-020-05601-y. View

15.

Young A, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C . Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023. DOI: 10.1200/JCO.2018.78.8034. View

16.

Khorana A, Francis C, Culakova E, Kuderer N, Lyman G . Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5(3):632-4. DOI: 10.1111/j.1538-7836.2007.02374.x. View

17.

Di Nisio M, Carrier M . Incidental venous thromboembolism: is anticoagulation indicated?. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):121-127. PMC: 6142551. DOI: 10.1182/asheducation-2017.1.121. View

18.

Lyman G, Carrier M, Ay C, Di Nisio M, Hicks L, Khorana A . American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021; 5(4):927-974. PMC: 7903232. DOI: 10.1182/bloodadvances.2020003442. View

19.

Mulder F, Di Nisio M, Ay C, Carrier M, Bosch F, Segers A . Clinical implications of incidental venous thromboembolism in cancer patients. Eur Respir J. 2019; 55(2). DOI: 10.1183/13993003.01697-2019. View

20.

Key N, Khorana A, Kuderer N, Bohlke K, Lee A, Arcelus J . Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019; 38(5):496-520. DOI: 10.1200/JCO.19.01461. View